ALT
NASDAQ HealthcareAltimmune, Inc. - Common Stock
Biotechnology
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
๐ Market Data
| Price | $3.25 |
|---|---|
| Volume | 12,175,720 |
| Market Cap | 632.18M |
| Beta | 0.180 |
| RSI (14-Day) | 59.2 |
| 200-Day MA | $3.57 |
| 50-Day MA | $3.06 |
| 52-Week High | $6.44 |
| 52-Week Low | $2.56 |
| Forward P/E | -4.86 |
| Price / Book | 1.33 |
๐ฏ Investment Strategy Scores
ALT scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (85/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Moon Shot (6/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ALT in your text
Paste any article, transcript, or post โ the tool will extract ALT and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-18.